Identity
- Trade Name
- KBA.62 (KBA.62) Mouse Monoclonal Antibody FDA UDI
- Generic Name
- Melanoma specific protein IVD, antibody FDA UDI
- Model / Reference
- 366M-95 FDA UDI
Identifiers
- Primary DI / UDI-DI
- 00841683139294 FDA UDI
- FDA Product Code
- NJT FDA UDI
- GMDN Term
- Melanoma specific protein IVD, antibody FDA UDI
Classification
- Device Class
- Class I FDA UDI
- Regulation Number
- 864.1860 FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
No
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
Yes
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Melanoma specific protein IVD, antibody
KBA.62 (KBA.62) Mouse Monoclonal Antibody by Cell Marque Corporation — Class I — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Melanoma specific protein IVD, antibody.
- Dako — Agilent Technologies Inc. · Class I
- ihcDirect® PRAME Ab-Enh 15mL — NOVODIAX, INC. · Class I
- BOND — Leica Biosystems Newcastle, Limited · Class I
- ANTI-MELANOMA — Biogenex Laboratories, Inc. · Class I
- Tissue-Tek Genie® — Sakura Finetek USA, Inc · Class I
- ihcDirect® PRAME Ab Conjugate 5mL — NOVODIAX, INC. · Class I
- Q-STAIN® QSX-Enh PRAME — NOVODIAX, INC. · Class I
- Tissue-Tek Genie® — Sakura Finetek USA, Inc · Class I
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class I | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Cell Marque Corporation
Sources (1)
- FDA UDI 9197aba2-3653-4bee-95d1-73bb81f13328 33 fields · synced May 30, 2026